INSULIN RESISTANCE IN MOOD DISORDERS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。我们假设胰岛素抵抗（IR）水平高的参与者，如葡萄糖耐量测试（GTT）的反应所确定的，将表现出更大的认知缺陷。此外，我们假设IR患者在接受胰岛素增敏药物二甲双胍治疗后会表现出认知改善。终点：我们的第一个假设是，根据对GTT的反应，具有高水平IR的参与者将表现出更大的认知缺陷，这将通过将GTT数据与神经认知数据相关联来回答。我们的第二个假设是，IR患者在接受胰岛素增敏药物治疗后会表现出认知改善，这将通过测试二甲双胍治疗后神经认知数据的变化来回答。此外，我们将检测二甲双胍治疗后IR的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We hypothesize that participants with high levels of insulin resistance (IR), as determined by response to glucose tolerance testing (GTT), will show greater cognitive deficits. Further, we hypothesize that participants with IR will demonstrate cognitive improvement after treatment with Metformin, an insulin-sensitizing medication. Endpoints: Our first hypothesis, that participants with high levels of IR, as determined by response to GTT, will show greater cognitive deficits, will be answered by correlating GTT data with neurocognitive data. Our second hypothesis, that participants with IR will demonstrate cognitive improvement after treatment with an insulin-sensitizing medication, will be answered by testing for changes in neurocognitive data after treatment with Metformin. Further, we will test for changes in IR after treatment with Metformin.